Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial
The Lancet Diabetes and Endocrinology - Netherlands
doi 10.1016/s2213-8587(17)30013-x
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2017
Authors
Publisher
Elsevier BV